NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

ILMN

Illumina Inc

May 16 • 04:00PM ET

83.62

Dollar change +2.72
Percentage change 3.36	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: PACB VRTX TXG QGEN GH BIO MYGN IONS TWST OMIC

| Held by: IJH VTI VXF VB VO MDY VBR VUG IBB ARKK

Index	-	P/E	-	EPS (ttm)	-6.10	Insider Own	2.88%	Shs Outstand	159.00M	Perf Week	10.37%
Market Cap	13.24B	Forward P/E	17.74	EPS next Y	4.71	Insider Trans	0.41%	Shs Float	153.74M	Perf Month	13.72%
Income	-965.00M	PEG	-	EPS next Q	1.01	Inst Own	99.61%	Short Float	3.62%	Perf Quarter	-16.58%
Sales	4.34B	P/S	3.05	EPS this Y	2.25%	Inst Trans	-4.34%	Short Ratio	2.23	Perf Half Y	-43.35%
Book/sh	14.89	P/B	5.61	EPS next Y	10.79%	ROA	-11.90%	Short Interest	5.56M	Perf Year	-25.56%
Cash/sh	7.81	P/C	10.70	EPS next 5Y	8.73%	ROE	-23.82%	52W Range	68.70 - 156.66	Perf YTD	-37.42%
Dividend Est.	-	P/FCF	15.11	EPS past 5Y	-	ROI	-21.94%	52W High	-46.62%	Beta	1.33
Dividend TTM	-	Quick Ratio	1.48	Sales past 5Y	5.55%	Gross Margin	66.38%	52W Low	21.72%	ATR (14)	3.60
Dividend Ex-Date	-	Current Ratio	1.86	EPS Y/Y TTM	25.55%	Oper. Margin	32.70%	RSI (14)	58.49	Volatility	4.29% 3.75%
Employees	10370	Debt/Eq	1.10	Sales Y/Y TTM	-3.47%	Profit Margin	-22.25%	Recom	2.38	Target Price	101.62
Option/Short	Yes / Yes	LT Debt/Eq	0.86	EPS Q/Q	203.98%	Payout	-	Rel Volume	0.94	Prev Close	80.90
Sales Surprise	1.52%	EPS Surprise	3.24%	Sales Q/Q	-3.25%	Earnings	May 08 AMC	Avg Volume	2.50M	Price	83.62
SMA20	7.70%	SMA50	5.49%	SMA200	-29.19%	Trades		Volume	2,338,051	Change	3.36%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-25	Reiterated	Citigroup	Neutral	$130 → $90
Feb-28-25	Downgrade	HSBC Securities	Buy → Hold	$100
Feb-10-25	Downgrade	Barclays	Equal Weight → Underweight	$130 → $100
Feb-07-25	Downgrade	TD Cowen	Buy → Hold	$177 → $140
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$190 → $165
Nov-12-24	Resumed	Morgan Stanley	Equal-Weight	$156
Oct-17-24	Upgrade	HSBC Securities	Hold → Buy	$180
Aug-28-24	Upgrade	Argus	Hold → Buy
Aug-16-24	Upgrade	Daiwa Securities	Neutral → Buy	$120 → $154
Aug-14-24	Upgrade	TD Cowen	Hold → Buy	$126 → $144
Aug-14-24	Upgrade	Barclays	Underweight → Equal Weight	$125
Jul-10-24	Upgrade	Citigroup	Neutral → Buy	$140
Jun-03-24	Resumed	Jefferies	Hold	$115
Jan-16-24	Downgrade	HSBC Securities	Buy → Hold
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$144
Dec-18-23	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$185
Dec-15-23	Upgrade	Bernstein	Underperform → Mkt Perform
Dec-14-23	Initiated	Stephens	Overweight	$170
Dec-14-23	Initiated	Guggenheim	Buy	$155
Dec-13-23	Initiated	Wolfe Research	Outperform	$175

Show Previous Ratings

May-14-25 04:05PM	Illumina To Webcast Upcoming Investor Conference (PR Newswire)
07:43AM	Illumina, Inc. (ILMN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-13-25 09:16AM	Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends (Zacks)
09:15AM	Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications (PR Newswire)
May-10-25 10:57AM	Illumina price target lowered to $135 from $160 at Stifel (TipRanks)
10:56AM	Loading…
May-09-25 10:56AM	SEC ends probe of Illuminas Grail acquisition (MedTech Dive)
09:10AM	Q1 2025 Illumina Inc Earnings Call (Thomson Reuters StreetEvents)
08:49AM	Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips (Zacks)
03:40AM	Illumina Inc (ILMN) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
May-08-25 07:30PM	Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:40PM	Analyst Report: Illumina, Inc. (Morningstar Research)
06:00PM	Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates (Zacks)
04:55PM	Illumina: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 (PR Newswire)
May-07-25 05:20PM	Illumina Q1 2025 Earnings Preview (Seeking Alpha)
08:26AM	Loading…
08:26AM	Q1 2025 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
May-06-25 08:38AM	Here's Why Artisan Mid Cap Fund Decided to Exit Illumina (ILMN) (Insider Monkey)
May-05-25 10:00AM	Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:15AM	Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
May-01-25 11:05AM	How AI And Robotics Are Transforming Real Estate (Seeking Alpha)
10:01AM	Illumina (ILMN) Earnings Expected to Grow: Should You Buy? (Zacks)
09:15AM	Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development (PR Newswire)
Apr-30-25 07:33AM	Baron Focused Growth Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-24-25 07:57AM	Should You Hold Illumina (ILMN)? (Insider Monkey)
01:15AM	Artisan Mid Cap Fund Q1 2025 Commentary (Seeking Alpha)
Apr-22-25 12:00PM	Patient Capital Management Q1 2025 Investment Review (Seeking Alpha)
Apr-21-25 04:47PM	This Cancer Test Could Become Routineand a Big Seller, Says Analyst (Barrons.com)
02:59PM	Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns (Insider Monkey)
Apr-18-25 05:05AM	Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks (StockStory)
05:00AM	Illumina, Tempus AI partner to drive genomic testing beyond cancer (MedTech Dive)
08:45AM	Loading…
Apr-16-25 08:45AM	Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations (GlobeNewswire)
Apr-15-25 12:54PM	Squawk Pod: VA Governor Youngkin on DOGE & $2.2B to Harvard on hold - 04/15/25 Audio Only (CNBC TV)
09:15AM	Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation (PR Newswire)
Apr-12-25 09:32AM	GRAIL's Galleri Progresses While Back In Accumulation Levels (Seeking Alpha)
Apr-10-25 04:05PM	Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 (PR Newswire) -6.61%
01:30PM	Analyst Report: Illumina, Inc. (Morningstar Research)
Apr-04-25 09:40AM	Here's Why Illumina (ILMN) is a Strong Value Stock (Zacks)
Apr-01-25 12:10PM	Argus cuts Illumina target, sees buying opportunity (TipRanks)
Mar-31-25 09:03AM	The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics (Zacks)
Mar-30-25 07:10AM	abrdn World Healthcare Fund Q4 2024 Commentary (Seeking Alpha)
03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
03:25AM	abrdn Healthcare Opportunities Fund Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
Mar-27-25 10:13AM	How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain (Investor's Business Daily)
08:35AM	Is Illumina Undervalued After An 83% Drop In Its Stock Price? (SeekingAlpha)
Mar-25-25 02:04PM	Cintas, UPS, Illumina: Market Minute (Yahoo Finance Video)
09:52AM	Activist Investor Meister to Join Illuminas Board (The Wall Street Journal)
09:10AM	Illumina shares rise on WSJ report activist investor Meister will join board (Investing.com)
09:00AM	Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors (PR Newswire)
08:18AM	Activist investor Keith Meister to join Illumina's board (Reuters)
Mar-24-25 12:36PM	Is Illumina, Inc. (ILMN) the Best Diagnostics Stock to Invest in Right Now? (InsiderMonkey)
11:47AM	Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain? (Zacks)
Mar-20-25 07:00AM	Invesco Global Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 09:15AM	Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery (PR Newswire)
Mar-18-25 09:40AM	Why Illumina (ILMN) is a Top Value Stock for the Long-Term (Zacks)
05:13AM	Illumina, Inc. (ILMN): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-17-25 09:23AM	Jim Cramer on Illumina (ILMN): A Challenged Company That He Doesnt Prefer (Insider Monkey)
Mar-11-25 09:46AM	Stocks to Watch Tuesday: Tesla, Southwest, Oracle, Illumina (The Wall Street Journal)
Mar-10-25 05:07PM	Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban (The Wall Street Journal)
04:22PM	Illumina lowers outlook due to China sales ban, to cut $100 million in costs (Reuters)
04:10PM	Illumina addresses recent developments in China (PR Newswire)
Mar-09-25 08:59PM	Why Illumina, Inc. (ILMN) Is Plunging So Far In 2025 (Insider Monkey)
Mar-07-25 04:01AM	3 Reasons to Sell ILMN and 1 Stock to Buy Instead (StockStory)
Mar-06-25 09:15AM	Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year (PR Newswire)
06:03AM	Illuminas DNA sequencers hit with China import ban (MedTech Dive)
Mar-05-25 12:54PM	China bans Illumina sequencer imports as US trade war intensifies (Medical Device Network)
Mar-04-25 04:47PM	Illumina Recoups Losses After China Retaliates Against Trump's Tariffs (Investor's Business Daily)
03:57PM	China bans imports of Illumina's gene sequencers amid tariff war (Yahoo Finance Video)
02:17PM	Illumina, airline downgrades, Walgreens: Market Minute (Yahoo Finance Video)
11:32AM	Illumina Stock Drops as China Bans Imports of Gene Sequencing Technology (Barrons.com)
11:31AM	Illumina Stock Slammed As China Retaliates Against Trump's Tariffs (Investor's Business Daily)
10:35AM	What's Left of Illumina's China Business After Tariff Retaliation: Heard on the Street (The Wall Street Journal)
08:52AM	Illumina slides as China bans imports of its gene sequencers (Investing.com)
12:57AM	China bans imports of Illumina's gene sequencers right after Trump tariff action (Reuters)
Mar-01-25 10:05AM	Trump Trade: Macron says leaving Washington with very little hope on tariffs (TipRanks)
Feb-28-25 04:12PM	Tariffs, Cut Funding Spur Illuminas Worst Month in 23 Years (Bloomberg) -5.12%
11:36AM	HSBC downgrades Illumina on China risks, funding concerns (Investing.com)
09:46AM	What Makes Illumina (ILMN) an Attractive Opportunity? (Insider Monkey)
09:40AM	Here's Why Illumina (ILMN) is a Strong Value Stock (Zacks)
05:00AM	Illumina to lay off 96 San Diego employees (MedTech Dive)
Feb-25-25 07:58AM	What Makes Illumina (ILMN) a Long Term Bet? (Insider Monkey)
05:35AM	Illuminas spatial transcriptomics to accelerate breakthroughs in biomedical science (Medical Device Network)
Feb-24-25 09:34AM	Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology (PR Newswire)
07:00AM	Trumps Early Policy Moves Create New Headaches for This Biotech Heavyweight (The Wall Street Journal)
Feb-21-25 09:15AM	Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions (PR Newswire)
Feb-20-25 08:16PM	Analyst Report: Illumina, Inc. (Morningstar Research) -5.63%
07:19AM	Illumina teases transcriptome profiling tech ahead of 2026 launch (Medical Device Network)
Feb-19-25 04:15PM	Cathie Wood Explains AI Growth Catalysts for Illumina (ILMN) (Insider Monkey)
09:15AM	Illumina unveils first-of-its-kind spatial transcriptomics technology (PR Newswire)
Feb-18-25 04:05PM	Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference (PR Newswire)
Feb-14-25 12:00AM	Calvin Klein blacklisting sends chill through US business in China (Financial Times)
Feb-13-25 01:57PM	Trumps Cuts to Medical Research Are Hurting These Stocks (Barrons.com)
01:43PM	Jim Cramer on Chinas Crackdown on Illumina (ILMN): There Are Two Other Companies That Do What They Do (Insider Monkey)
Feb-12-25 05:57PM	Trickle-down effect of NIH funding battle worries healthcare analysts and medical experts (Yahoo Finance)
09:45AM	Here's Why Illumina (ILMN) is a Strong Growth Stock (Zacks)
08:03AM	PacBio (PACB) Q4 Earnings Report Preview: What To Look For (StockStory)
Feb-11-25 09:40AM	Why Illumina (ILMN) is a Top Value Stock for the Long-Term (Zacks)
09:32AM	Why Illumina Inc. (ILMN) Went Down on Monday (Insider Monkey)
08:06AM	10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect (StockStory)
Feb-10-25 05:12PM	Why Illumina Stock Got Mashed on Monday (Motley Fool) -5.47%

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dhingra Ankur	SVP, Chief Financial Officer	May 12 '25	Buy	81.21	6,100	495,381	24,906	May 14 04:20 PM
Thaysen Jacob	Chief Executive Officer	May 12 '25	Buy	80.88	6,500	525,732	77,540	May 14 04:18 PM
Thaysen Jacob	Chief Executive Officer	May 13 '25	Buy	80.84	5,850	472,942	83,390	May 14 04:18 PM
JAKOB WEDEL CHRISTENSEN	Officer	May 06 '25	Proposed Sale	77.21	549	42,388		May 06 04:02 PM
ARNOLD FRANCES	Director	Feb 27 '25	Proposed Sale	93.48	120	11,218		Feb 27 11:07 AM
JAKOB WEDEL	Officer	Feb 18 '25	Proposed Sale	100.00	460	46,000		Feb 18 04:22 PM
PATRICIA L LECKMAN	Officer	Feb 18 '25	Proposed Sale	100.00	1,756	175,600		Feb 18 04:08 PM
CHARLES E. DADSWELL TRUST U/A/	Officer	Oct 14 '24	Proposed Sale	145.54	4,948	720,132		Oct 15 08:03 AM
CHARLES E. DADSWELL TRUST U/A/	Officer	Aug 15 '24	Proposed Sale	122.28	3,956	483,740		Aug 15 04:31 PM

Open in Screener

SMMT

Summit Therapeutics Inc

May 16 • 04:00PM ET

23.87

Dollar change +0.78
Percentage change 3.38	%

Healthcare • Biotechnology • USA • NASD

SMMT Summit Therapeutics Inc daily Stock Chart

Peers: VRTX REGN GILD NBIX ALNY BIIB AMGN SRPT AKTX PRTA

| Held by: VTI VB XBI IWM VXF VBR IWO IBB SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-0.33	Insider Own	85.03%	Shs Outstand	741.61M	Perf Week	-0.38%
Market Cap	17.61B	Forward P/E	-	EPS next Y	-0.56	Insider Trans	0.00%	Shs Float	110.45M	Perf Month	3.56%
Income	-240.75M	PEG	-	EPS next Q	-0.09	Inst Own	13.22%	Short Float	24.62%	Perf Quarter	11.70%
Sales	0.00M	P/S	-	EPS this Y	-31.11%	Inst Trans	8.38%	Short Ratio	6.69	Perf Half Y	14.98%
Book/sh	0.46	P/B	51.41	EPS next Y	-38.95%	ROA	-85.89%	Short Interest	27.19M	Perf Year	409.50%
Cash/sh	0.49	P/C	48.69	EPS next 5Y	-25.52%	ROE	-123.93%	52W Range	2.10 - 36.91	Perf YTD	33.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.52%	ROI	-69.33%	52W High	-35.33%	Beta	-0.99
Dividend TTM	-	Quick Ratio	10.63	Sales past 5Y	-8.94%	Gross Margin	-	52W Low	1036.67%	ATR (14)	2.49
Dividend Ex-Date	-	Current Ratio	10.63	EPS Y/Y TTM	-99.70%	Oper. Margin	-	RSI (14)	49.39	Volatility	7.34% 11.68%
Employees	159	Debt/Eq	0.02	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	37.38
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-37.64%	Payout	-	Rel Volume	0.41	Prev Close	23.09
Sales Surprise	-	EPS Surprise	3.23%	Sales Q/Q	-	Earnings	May 01 AMC	Avg Volume	4.06M	Price	23.87
SMA20	-7.32%	SMA50	6.65%	SMA200	21.38%	Trades		Volume	1,647,887	Change	3.38%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-25	Upgrade	Citigroup	Neutral → Buy	$23 → $35
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-12-25	Initiated	Evercore ISI	Outperform	$30
Feb-28-25	Initiated	Goldman	Buy	$42
Jan-08-25	Initiated	Truist	Buy	$35
Dec-11-24	Initiated	Wells Fargo	Overweight	$30
Dec-06-24	Initiated	Jefferies	Buy	$31
Nov-04-24	Initiated	JMP Securities	Mkt Outperform	$32
Sep-27-24	Downgrade	Citigroup	Buy → Neutral	$19 → $23
Aug-12-24	Initiated	H.C. Wainwright	Buy	$16
May-07-24	Initiated	Citigroup	Buy	$7
Mar-26-24	Initiated	Stifel	Buy	$8
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy	$30 → $27
Feb-13-18	Initiated	BTIG Research	Buy	$33
Jan-04-18	Initiated	SunTrust	Buy	$24
Dec-01-17	Resumed	H.C. Wainwright	Buy	$16
Nov-16-16	Reiterated	RBC Capital Mkts	Outperform	$26 → $29
Oct-05-16	Reiterated	Needham	Buy	$22 → $30

Show Previous Ratings

May-16-25 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-25 10:37AM	Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-07-25 09:30AM	Can Summit Therapeutics Stock Double Your Money? (Motley Fool)
May-06-25 09:55AM	Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know (Zacks) -13.63%
May-04-25 05:39AM	Why Summit Therapeutics Inc. (SMMT) Soared Last Week (Insider Monkey)
09:01AM	Loading…
May-02-25 09:01AM	Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil (Zacks) +13.09%
08:30AM	This Soaring Stock Just Delivered More Good News. Time to Buy? (Motley Fool)
01:06AM	Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
May-01-25 04:09PM	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 (Business Wire)
Apr-28-25 07:48AM	Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat? (Zacks)
Apr-26-25 12:50PM	Akeso survival data for ivonescimab misses expectations, STAT says (TipRanks)
09:30AM	Summit Therapeutics: New Ivonescimab Data Raise Concerns (Seeking Alpha)
Apr-25-25 05:05PM	Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today (Motley Fool) -36.06%
02:50PM	Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China (Business Wire)
Apr-24-25 04:15PM	Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 (Business Wire) +10.44%
08:00AM	Loading…
08:00AM	Akeso and Summit notch another Phase III win with their Keytruda competitor (Clinical Trials Arena)
Apr-23-25 06:13PM	Why Summit Therapeutics Inc. (SMMT) Went Up On Wednesday (Insider Monkey) +21.50%
04:10PM	BioNTech Surges On Summit's Coattails. But Can They Take On Merck? (Investor's Business Daily)
04:05PM	Why Summit Therapeutics Rocketed Double-Digits Today (Motley Fool)
03:47PM	Why Is Summit Therapeutics Stock Soaring On Wednesday? (Benzinga)
06:15AM	Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China (Business Wire)
05:45AM	This Company's Co-CEOs Just Bought More Shares. Should You? (Motley Fool)
Apr-22-25 07:32AM	Merck Q1 Earnings Coming Up: Should You Buy the Stock Now? (Zacks) +8.45%
Apr-20-25 10:15AM	Bullish On Akeso's Ivonescimab, But Valuation And Geopolitical Risks Remain (Seeking Alpha)
Apr-19-25 07:40AM	What Moved Markets This Week (Seeking Alpha)
Apr-15-25 12:40AM	Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? (Insider Monkey) -5.78%
Apr-14-25 09:08AM	Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition (Seeking Alpha) +12.44%
05:57AM	Here's Why Summit Therapeutics Stock Soared 15% on Friday (Zacks)
Apr-12-25 06:45PM	Why Summit Therapeutics Inc. (SMMT) Soared Last Week? (Insider Monkey)
02:45PM	3 Magnificent Stocks That Could Double or More by 2030 (Motley Fool)
12:35PM	Loading…
12:35PM	Summit Therapeutics: Not Pharmacyclics, Not Yet (Seeking Alpha)
02:10AM	Why Summit Therapeutics Inc. (SMMT) Surged On Friday? (Insider Monkey)
Apr-11-25 12:15PM	Summit co-CEO option exercise quite bullish, says Cantor Fitzgerald (TipRanks) +15.33%
12:10PM	Expert says Summits HARMONi-2 study could beat expectations, says Truist (TipRanks)
06:46AM	Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday? (Insider Monkey)
Apr-10-25 04:36PM	Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets (Motley Fool) +10.53%
Apr-06-25 07:02AM	2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade (Motley Fool)
Apr-04-25 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.20%
Apr-03-25 11:30AM	Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? (Zacks) -7.58%
09:45AM	3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months (Motley Fool)
Mar-31-25 03:25PM	Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today (Motley Fool) -5.07%
04:53AM	Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. (Motley Fool)
Mar-30-25 11:35AM	Street Calls of the Week (Investing.com)
Mar-28-25 11:30AM	Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? (Zacks)
07:30AM	Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade) (Seeking Alpha)
Mar-26-25 05:21PM	Why Summit Therapeutics Stock Slipped Today (Motley Fool)
09:28AM	Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook (SeekingAlpha)
Mar-23-25 05:49AM	Is Summit Therapeutics a Millionaire Maker? (Motley Fool)
Mar-21-25 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-19-25 10:11AM	Merck Loses Almost $52B in 6 Months: How to Play MRK Stock (Zacks)
09:00AM	This Unstoppable Biotech Stock Just Became an Even Better Buy (Fool)
Mar-17-25 04:24PM	Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer (Business Wire)
Mar-14-25 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.34%
08:13AM	Why Summit Therapeutics Stock Was Winning This Week (Motley Fool)
Mar-13-25 07:04PM	Is Summit Therapeutics Inc. (SMMT) the Best Multibagger Stock to Buy in 2025? (Insider Monkey)
07:30AM	This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year (Motley Fool)
Mar-08-25 06:39PM	Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? (Insider Monkey)
Mar-04-25 01:00AM	Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda (BioPharma Dive)
Feb-27-25 01:14PM	Summit Therapeutics Inc. (SMMT): Among the Stocks That Will Go to the Moon According to Analysts (Insider Monkey)
Feb-25-25 11:17AM	Why Summit Therapeutics Inc. (SMMT) Went Down On Monday? (Insider Monkey)
03:56AM	Q4 2024 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:01AM	Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Feb-24-25 12:52PM	Pfizer sets sights on Summits bispecific in combo with its ADCs (Pharmaceutical Technology) -14.83%
12:43PM	Is Summit Therapeutics (SMMT) One of the Best Growth Stocks to Invest In According to Analysts? (Insider Monkey)
10:13AM	Summit Therapeutics Stock Sinks as Firm Reports Widening Loss (Investopedia)
06:05AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024 (Business Wire)
06:00AM	Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs) (Business Wire)
Feb-18-25 09:00AM	Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025 (Business Wire)
Feb-17-25 04:32AM	3 Stocks That Could Trounce the Market in 2025 (Motley Fool)
Feb-14-25 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-09-25 06:15AM	Is Summit Therapeutics a Millionaire Maker? (Motley Fool)
Feb-08-25 09:01AM	Why Summit Therapeutics Inc. (SMMT) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
08:50AM	2 Stocks That Could Soar Again in 2025 (Motley Fool)
Feb-07-25 05:30AM	The Drug Industry Is Having Its Own DeepSeek Moment (The Wall Street Journal)
Feb-03-25 01:11PM	Summit Therapeutics (SMMT): Jim Cramer Calls It a Very Big Spec (Insider Monkey) -7.07%
Jan-30-25 09:15AM	Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? (Motley Fool)
Jan-29-25 03:58PM	Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? (Insider Monkey) -7.91%
Jan-26-25 02:40AM	Why Summit Therapeutics (SMMT) Is Skyrocketing Now (Insider Monkey)
Jan-23-25 05:47AM	3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% (Motley Fool)
Jan-21-25 12:06PM	Why Summit Therapeutics Stock Is Jumping Today (Motley Fool) +16.13%
Jan-20-25 07:00PM	Heres Why Analysts Are Bullish on Summit Therapeutics Inc. (SMMT) (Insider Monkey)
Jan-18-25 05:52PM	Is Summit Therapeutics (SMMT) the Best Russell 2000 Stock to Invest in According to Analysts? (Insider Monkey)
Jan-16-25 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-15-25 09:35AM	Why Summit Therapeutics Rocketed 584% in 2024 (Motley Fool) +9.31%
Jan-07-25 07:00AM	Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-04-25 06:48AM	Prediction: These 3 Healthcare Stocks Will Soar in 2025 (Motley Fool)
Jan-01-25 12:45PM	Why Is Summit Therapeutics Inc. (SMMT) Among the Best Multibagger Stocks to Buy Right Now? (Insider Monkey)
Dec-29-24 06:47AM	3 Stocks That Could Be Monster Winners in 2025 (Motley Fool)
Dec-23-24 10:36AM	Is Summit Therapeutics Inc. (SMMT) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-20-24 10:21AM	Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? (Insider Monkey)
06:30AM	Where Will Summit Therapeutics Be in 5 Years? (Motley Fool)
04:50AM	3 Stocks That Could Turn $1,000 into $5,000 by 2030 (Motley Fool)
Dec-18-24 05:44AM	3 No-Brainer Biotech Stocks to Buy With $200 Right Now (Motley Fool) -8.56%
Dec-15-24 07:37AM	2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street (Motley Fool)
Dec-14-24 04:00PM	Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today (Motley Fool)
Dec-13-24 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-06-24 07:09PM	Why Summit Therapeutics Stock Rocketed 6% Higher on Friday (Motley Fool) +5.82%
Dec-02-24 04:22AM	Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher (Motley Fool)
Nov-30-24 06:05AM	Warning: This Skyrocketing Stock Has a Hidden Risk (Motley Fool)
Nov-26-24 04:15PM	Summit Therapeutics to Present at Upcoming Investor Conferences (Business Wire)

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

ILMN

Illumina Inc

SMMT

Summit Therapeutics Inc

Upgrade your FINVIZ experience